403 related articles for article (PubMed ID: 25745085)
1. Mesenchymal stem cell-mediated, tumor stroma-targeted radioiodine therapy of metastatic colon cancer using the sodium iodide symporter as theranostic gene.
Knoop K; Schwenk N; Schmohl K; Müller A; Zach C; Cyran C; Carlsen J; Böning G; Bartenstein P; Göke B; Wagner E; Nelson PJ; Spitzweg C
J Nucl Med; 2015 Apr; 56(4):600-6. PubMed ID: 25745085
[TBL] [Abstract][Full Text] [Related]
2. Stromal targeting of sodium iodide symporter using mesenchymal stem cells allows enhanced imaging and therapy of hepatocellular carcinoma.
Knoop K; Schwenk N; Dolp P; Willhauck MJ; Zischek C; Zach C; Hacker M; Göke B; Wagner E; Nelson PJ; Spitzweg C
Hum Gene Ther; 2013 Mar; 24(3):306-16. PubMed ID: 23402366
[TBL] [Abstract][Full Text] [Related]
3. Radiation-Induced Amplification of TGFB1-Induced Mesenchymal Stem Cell-Mediated Sodium Iodide Symporter (
Schug C; Kitzberger C; Sievert W; Spellerberg R; Tutter M; Schmohl KA; Eberlein B; Biedermann T; Steiger K; Zach C; Schwaiger M; Multhoff G; Wagner E; Nelson PJ; Spitzweg C
Clin Cancer Res; 2019 Oct; 25(19):5997-6008. PubMed ID: 31196853
[TBL] [Abstract][Full Text] [Related]
4. Effective control of tumor growth through spatial and temporal control of theranostic sodium iodide symporter (
Tutter M; Schug C; Schmohl KA; Urnauer S; Schwenk N; Petrini M; Lokerse WJM; Zach C; Ziegler S; Bartenstein P; Weber WA; Wagner E; Lindner LH; Nelson PJ; Spitzweg C
Theranostics; 2020; 10(10):4490-4506. PubMed ID: 32292510
[No Abstract] [Full Text] [Related]
5. Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery.
Müller AM; Schmohl KA; Knoop K; Schug C; Urnauer S; Hagenhoff A; Clevert DA; Ingrisch M; Niess H; Carlsen J; Zach C; Wagner E; Bartenstein P; Nelson PJ; Spitzweg C
Oncotarget; 2016 Aug; 7(34):54795-54810. PubMed ID: 27458162
[TBL] [Abstract][Full Text] [Related]
6. TGFB1-driven mesenchymal stem cell-mediated NIS gene transfer.
Schug C; Urnauer S; Jaeckel C; Schmohl KA; Tutter M; Steiger K; Schwenk N; Schwaiger M; Wagner E; Nelson PJ; Spitzweg C
Endocr Relat Cancer; 2019 Jan; 26(1):89-101. PubMed ID: 30121623
[TBL] [Abstract][Full Text] [Related]
7. Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery.
Knoop K; Kolokythas M; Klutz K; Willhauck MJ; Wunderlich N; Draganovici D; Zach C; Gildehaus FJ; Böning G; Göke B; Wagner E; Nelson PJ; Spitzweg C
Mol Ther; 2011 Sep; 19(9):1704-13. PubMed ID: 21587211
[TBL] [Abstract][Full Text] [Related]
8. A Novel Approach for Image-Guided
Schug C; Gupta A; Urnauer S; Steiger K; Cheung PF; Neander C; Savvatakis K; Schmohl KA; Trajkovic-Arsic M; Schwenk N; Schwaiger M; Nelson PJ; Siveke JT; Spitzweg C
Mol Cancer Res; 2019 Jan; 17(1):310-320. PubMed ID: 30224540
[TBL] [Abstract][Full Text] [Related]
9. Systemic tumor-targeted sodium iodide symporter (NIS) gene therapy of hepatocellular carcinoma mediated by B6 peptide polyplexes.
Urnauer S; Klutz K; Grünwald GK; Morys S; Schwenk N; Zach C; Gildehaus FJ; Rödl W; Ogris M; Wagner E; Spitzweg C
J Gene Med; 2017 May; 19(5):. PubMed ID: 28423213
[TBL] [Abstract][Full Text] [Related]
10. Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene.
Klutz K; Russ V; Willhauck MJ; Wunderlich N; Zach C; Gildehaus FJ; Göke B; Wagner E; Ogris M; Spitzweg C
Clin Cancer Res; 2009 Oct; 15(19):6079-86. PubMed ID: 19789324
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal Stem Cell-mediated Image-guided Sodium Iodide Symporter (NIS) Gene Therapy Improves Survival of Glioblastoma-bearing Mice.
Kitzberger C; Spellerberg R; Han Y; Schmohl KA; Stauss C; Zach C; Kälin RE; Multhoff G; Eiber M; Schilling F; Glass R; Weber WA; Wagner E; Nelson PJ; Spitzweg C
Clin Cancer Res; 2023 Mar; 29(5):930-942. PubMed ID: 36516189
[TBL] [Abstract][Full Text] [Related]
12. Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma.
Niess H; Bao Q; Conrad C; Zischek C; Notohamiprodjo M; Schwab F; Schwarz B; Huss R; Jauch KW; Nelson PJ; Bruns CJ
Ann Surg; 2011 Nov; 254(5):767-74; discussion 774-5. PubMed ID: 22042469
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer.
Scholz IV; Cengic N; Baker CH; Harrington KJ; Maletz K; Bergert ER; Vile R; Göke B; Morris JC; Spitzweg C
Gene Ther; 2005 Feb; 12(3):272-80. PubMed ID: 15510175
[TBL] [Abstract][Full Text] [Related]
14. Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene.
Grünwald GK; Vetter A; Klutz K; Willhauck MJ; Schwenk N; Senekowitsch-Schmidtke R; Schwaiger M; Zach C; Wagner E; Göke B; Holm PS; Ogris M; Spitzweg C
J Nucl Med; 2013 Aug; 54(8):1450-7. PubMed ID: 23843567
[TBL] [Abstract][Full Text] [Related]
15. Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene.
Schmohl KA; Gupta A; Grünwald GK; Trajkovic-Arsic M; Klutz K; Braren R; Schwaiger M; Nelson PJ; Ogris M; Wagner E; Siveke JT; Spitzweg C
Oncotarget; 2017 May; 8(20):33393-33404. PubMed ID: 28380420
[TBL] [Abstract][Full Text] [Related]
16. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression.
Spitzweg C; Baker CH; Bergert ER; O'Connor MK; Morris JC
Hum Gene Ther; 2007 Oct; 18(10):916-24. PubMed ID: 17931047
[TBL] [Abstract][Full Text] [Related]
17. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.
Mitrofanova E; Unfer R; Vahanian N; Link C
Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal Stem Cell-mediated delivery of the sodium iodide symporter supports radionuclide imaging and treatment of breast cancer.
Dwyer RM; Ryan J; Havelin RJ; Morris JC; Miller BW; Liu Z; Flavin R; O'Flatharta C; Foley MJ; Barrett HH; Murphy JM; Barry FP; O'Brien T; Kerin MJ
Stem Cells; 2011 Jul; 29(7):1149-57. PubMed ID: 21608083
[TBL] [Abstract][Full Text] [Related]
19. Telomerase-driven expression of the sodium iodide symporter (NIS) for in vivo radioiodide treatment of cancer: a new broad-spectrum NIS-mediated antitumor approach.
Riesco-Eizaguirre G; De la Vieja A; Rodríguez I; Miranda S; Martín-Duque P; Vassaux G; Santisteban P
J Clin Endocrinol Metab; 2011 Sep; 96(9):E1435-43. PubMed ID: 21697253
[TBL] [Abstract][Full Text] [Related]
20. Application of 188rhenium as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression.
Willhauck MJ; Sharif Samani BR; Gildehaus FJ; Wolf I; Senekowitsch-Schmidtke R; Stark HJ; Göke B; Morris JC; Spitzweg C
J Clin Endocrinol Metab; 2007 Nov; 92(11):4451-8. PubMed ID: 17698909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
